Clinical Pipelines: What are the Cell and Gene Therapies of the Future?
Clinical Pipelines: Neurology and Ophthalmology
Clinical Pipelines: Developments in Stem Cell Therapeutics and Regenerative Medicine
Clinical Pipelines: Gene Therapy to Treat Rare and Difficult Indications
Clinical Pipelines: Cell Therapy for Solid Tumors
Clinical Pipelines: Future Therapies for Non-Oncology Indications
Clinical Pipelines: Allogeneic Cellular Therapies
Clinical Pipelines: TCR and NK Cell Therapeutics

Clinical Pipelines: What are the Cell and Gene Therapies of the Future?

26 Jan 2022
Ori Biotech
WuXi Apptec

11:00 Chairperson’s Opening
Speaker TBD

11:05 Presentation 1
Kent Christopherson, Senior Director, Medical Affairs, Orchard Therapeutics

11:20 Future Technology Today: Manufacturing Innovations to Accelerate the Generation of Cell and Gene Therapies

  • Improving delivery, specificity and expression control of therapeutic transgenes through promoter and capsid engineering
  • Increasing viral vector yields and quality through plasmid engineering for AAV and lentiviral systems
  • Integrating GMP manufacturing and testing platforms accelerate time to market
  • Innovative technologies for plasmid free manufacture of viral vectors using XLenti stable and TESSA technology

Ryan Cawood, Chief Scientific Officer, WuXi Advanced Therapeutics and OxGene

11:35 The Future of Cell Therapy: Compelling Biological Features of Allogeneic Off-the-Shelf T Cells

  • Discuss the attributes of allogeneic T cells that make them a promising platform for treating disease
  • Explore the evolution of CAR T designs and technologies
  • Highlight how equipping T cells with next-generation armoring can overcome the hostile tumor microenvironment
  • Discuss benefits of a platform that doesn’t require HLA or TCR gene editing and implications for safety, expansion, and persistence

Pascal Touchon, President and Chief Executive Officer, Atara Biotherapeutics

11:50 Presentation 4
Jason C. Foster, Chief Executive Officer, Ori Biotech

12:05 Speaker Q&A and Panel Discussion


Kent Christopherson
Senior Director, Medical Affairs
Orchard Therapeutics
Ryan Cawood
Chief Scientific Officer
WuXi Apptec
Pascal Touchon
President and Chief Executive Officer
Atara Biotherapeutics
Jason C. Foster
Chief Executive Officer
Ori Biotech